The FDA denied a petition from Harrison.ai seeking partial exemption from premarket review for certain diagnostic and detection AI devices, provided the manufacturer has 510(k) clearance for a similar category. The decision maintains what the FDA described as the regulatory status quo and requires a robust postmarket plan. The denial matters for developers pursuing AI-enabled diagnostics because it signals continued constraints on pathways that would reduce upfront review requirements. It also increases the compliance burden for firms aiming to reuse existing 510(k)-cleared device frameworks for new AI use cases. For biotech and med-tech investors, the action is another datapoint in how the FDA is calibrating risk-based oversight for adaptive or software-centric diagnostic tools.